Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 326

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part II, Item 2
Chunk 326
---
 Contents

Item 5. Other Information

(a) Disclosure in lieu of reporting on a Current Report on Form 8-K.

      None.

(b) Material changes to the procedures by which security holders may recommend nominees to the board of directors.

      None.

(c) Insider Trading Arrangements and Policies

During the three months ended September 30, 2025, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

EXHIBIT INDEX

Incorporated by ReferenceFiled/FurnishedHerewithExhibit NumberExhibit DescriptionFormFile No.ExhibitFilingDate3.1Amended and Restated Certificate of Incorporation of Immuneering Corporation10-Q001-406753.19/9/20213.2Amended and Restated Bylaws of Immuneering Corporation8-K001-406753.12/2/20244.1Form of Pre-Funded Warrant8-K001-406754.18/25/20254.2Form of Purchase Warrant8-K001-406754.28/25/202510.1#Immuneering Corporation Non-Employee Director Compensation Program, as amended, effective August 12, 2025*10.2Equity Distribution Agreement, dated as of August 13, 2025, by and between Immuneering Corporation and Piper Sandler & Co.S-3333-2895891.28/13/202510.3##Form of Securities Purchase Agreement, dated as of August 21, 2025, by and among Immuneering Corporation and the investors party thereto8-K001-4067510.18/25/202510.4Form of Registration Rights Agreement, dated as of August 21, 2025, by and among Immuneering Corporation and the investors party thereto8-K001-4067510.28/25/202510.5##Securities Purchase Agreement, dated as of September 24, 2025, by and between Immuneering Corporation and Aventis Inc.8-K001-4067510.19/24/202531.1Certification of Principal Executive Officer pursuant to Rule 13a-14